This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in pan-tumor HER2 testing in patients with advanced solid tumors and of treatment options based on HER2 results. This activity will also address designing laboratory workflows to achieve efficient, accurate, and equitable pan-tumor HER2 testing. The microlearning design of this activity allows for a brief and focused exploration of this topic.
Course topics include:
- HER2 signaling pathway
- HER2 amplification and overexpression and its prevalence in various solid tumors
- DESTINY-PanTumor02 and the recent FDA pan-tumor approval
- HER2 IHC scoring guidelines
- Specimen handing and biomarker reporting
- HER2 IHC with different antibodies and tumor heterogeneity
- Treatment implications for patients based on HER2 results
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
Upon completion of this activity, you will be able to:
- Identify when HER2 testing may be indicated in patients with advanced solid tumors
- Describe how the use of certain HER2-directed therapy may impact clinical outcomes in patients with different types of solid tumors
- Outline how HER2 testing may be performed in different types of solid tumors
- Design laboratory workflows to achieve efficient, accurate, and equitable pan-tumor HER2 testing
- Lead collaborative efforts with members of the clinical and laboratory teams to establish HER2 testing decision trees and protocols
Faculty
Wei Zhang, MD, PhD
Associate Professor, Medical Director of Molecular Pathology (Solid Tumor)
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center
Kansas City, Kansas
Faculty Disclosures
Wei Zhang has no financial relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of .25 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must participate in the course. CME certificates will be provided on-line.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.